NHC director exercises options for 7,500 shares
NATIONAL HEALTHCARE CORP director Richard F. LaRoche Jr. exercised stock options to acquire 7,500 shares of common stock on 2026-05-05 at an exercise price of $71.64 per share.
Rhea-AI Filing Summary
NATIONAL HEALTHCARE CORP director Richard F. LaRoche Jr. exercised stock options to acquire 7,500 shares of common stock on 2026-05-05 at an exercise price of $71.64 per share. After this derivative exercise, he directly holds 213,260 common shares.
He also retains four additional option grants under the company’s equity plans, each for 7,500 underlying shares, with exercise prices between $55.75 and $96.03 and expiration dates from 2027-05-04 through 2030-05-07, indicating a continuing equity stake through unexercised options.
Positive
- None.
Negative
- None.
Insider Trade Summary
7,500 shares exercised/converted
Exercise
6 txns
Insider
LAROCHE RICHARD F JR
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Option to Purchase Common Stock [2021 Grant] | 7,500 | $0.00 | $0.00 |
| Exercise | Common Stock - Held in my name or my wife's name | 7,500 | $71.64 | $537K |
| holding | Option to Purchase Common Stock [2022 Grant] | -- | -- | -- |
| holding | Option to Purchase Common Stock [2023 Grant] | -- | -- | -- |
| holding | Option to Purchase Common Stock [2024 Grant] | -- | -- | -- |
| holding | Option to Purchase Common Stock [2025 Grant] | -- | -- | -- |
Holdings After Transaction:
Option to Purchase Common Stock [2021 Grant] — 0 contracts (Direct);
Common Stock - Held in my name or my wife's name — 213,260 shares (Direct);
Option to Purchase Common Stock [2022 Grant] — 7,500 contracts (Direct);
Option to Purchase Common Stock [2023 Grant] — 7,500 contracts (Direct);
Option to Purchase Common Stock [2024 Grant] — 7,500 contracts (Direct);
Option to Purchase Common Stock [2025 Grant] — 7,500 contracts (Direct)
Footnotes (1)
- F1. These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan on May 6, 2021. The grant and exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d).
Key Figures
Options exercised: 7,500 shares
Exercise price: $71.64 per share
Shares held after: 213,260 shares
+2 more
5 metrics
Options exercised
7,500 shares
Common stock acquired via derivative exercise on 2026-05-05
Exercise price
$71.64 per share
Exercise price for 2021 option grant converted to common stock
Shares held after
213,260 shares
Director’s direct common stock holdings following the transaction
Remaining option grants
4 grants × 7,500 underlying shares
Unexercised options in derivativeSummary
Remaining option exercise prices
$55.75–$96.03 per share
Exercise prices for 2022–2025 grants expiring 2027–2030
Key Terms
Option to Purchase Common Stock, derivative exercise/conversion, 2020 Omnibus Equity Incentive Plan, Section 16(b), +1 more
5 terms
Option to Purchase Common Stock financial
"security_title: "Option to Purchase Common Stock [2025 Grant]""
derivative exercise/conversion financial
"transaction_action: "derivative exercise/conversion" for code M"
2020 Omnibus Equity Incentive Plan financial
"These stock options were granted pursuant to the 2020 Omnibus Equity Incentive Plan"
Section 16(b) regulatory
"The grant and exercise of these stock options are exempt from Section 16(b)"
A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.
Rule 16b-3(d) regulatory
"exempt from Section 16(b) pursuant to Rule 16b-3(d)"
Rule 16b-3(d) is a narrow SEC safe-harbor that shields company insiders (officers, directors and large shareholders) from liability for short‑swing profits when their buys or sells of company stock are made under a pre-established, written plan or contract that removes the insider’s ability to time trades. For investors, this matters because it permits predictable, automated insider transactions — like scheduled sales for diversification or payroll withholding — without triggering forced disgorgement, so such planned trades are treated differently from opportunistic insider trading.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did NATIONAL HEALTHCARE CORP (NHC) disclose on this Form 4?
NATIONAL HEALTHCARE CORP reported that director Richard F. LaRoche Jr. exercised options for 7,500 common shares on 2026-05-05. The transaction used an exercise price of $71.64 per share and increased his directly held common stock position.
What options did the NATIONAL HEALTHCARE CORP (NHC) director exercise in this Form 4?
The director exercised an “Option to Purchase Common Stock [2021 Grant]” covering 7,500 underlying shares at an exercise price of $71.64 per share. This derivative exercise converted the options into an equal number of NATIONAL HEALTHCARE CORP common shares.
What unexercised stock options does the NATIONAL HEALTHCARE CORP (NHC) director still hold?
The Form 4 shows four remaining option grants, each for 7,500 underlying shares. Exercise prices are $94.66, $96.03, $55.75, and $69.19 per share, with expiration dates between 2027-05-04 and 2030-05-07, indicating ongoing option-based exposure.
Under which plan were the NATIONAL HEALTHCARE CORP (NHC) options granted to the director?
A footnote states the stock options were granted under the 2020 Omnibus Equity Incentive Plan on 2021-05-06. It also notes the grant and exercise are exempt from Section 16(b) short-swing profit rules under SEC Rule 16b-3(d).
AI-generated analysis. How Rhea-AI works. Not financial advice.
